verzenios
eli lilly nederland b.v. - abemaciclib - sânii neoplasme - agenți antineoplazici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
zitazonium 10 mg comprimate
egis pharmaceuticals plc - tamoxifenum - comprimate - 10 mg
falvax 250 mg
betapharm arzneimittel gmbh - germania - fulvestrantum - sol. inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni
vastaloma 250 mg
laboratorios farmalan s.a. - spania - fulvestrantum - sol. inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni
fulvestrant cipla 250 mg
laboratorios farmalan, s.a. - spania - fulvestrantum - sol inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni
afinitor comprimate 2,5 mg
novartis pharma ag - everolimus - comprimate - 2,5 mg
egitumab pulbere si solvent pentru solutie perfuzabila 440 mg
celltrion healthcare co. ltd. - trastuzumabum - pulbere si solvent pentru solutie perfuzabila - 440 mg
femara comprimate filmate 2,5 mg
novartis pharma ag - letrozolum - comprimate filmate - 2,5 mg
herceptin pulbere pentru solutie perfuzabila 150 mg
roche registration ltd - trastuzumabum - pulbere pentru solutie perfuzabila - 150 mg
herceptin 600 mg/5 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - trastuzumabum - soluţie injectabilă - 600 mg/5 ml